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Abstract
Background The clinical and economic management of retinal diseases has become more complex following the introduc-
tion of new intravitreal treatments. Multicriteria decision analysis (MCDA) offers the potential to overcome the challenges 
associated with traditional decision-making tools.
Objectives A MCDA to determine the most relevant criteria to decision-making in the management of diabetic macular 
edema (DME) based on the perspectives of multiple stakeholders in Spain was developed. This MCDA was termed the 
MULTIDEX-EMD study.
Methods Nineteen stakeholders (7 physicians, 4 pharmacists, 5 health authorities and health management experts, 1 psy-
chologist, and 2 patient representatives) participated in this three-phase project. In phase A, an advisory board defined all of 
the criteria that could influence DME treatment decision-making. These criteria were then screened using a discrete choice 
experiment (DCE) (phase B). Next, a multinomial logit model was fitted by applying the backward elimination algorithm 
(relevant criteria: p value < 0.05). Finally, the results were discussed in a deliberative process (phase C).
Results Thirty-one criteria were initially defined (phase A) and grouped into 5 categories: efficacy/effectiveness, safety, 
organizational and economic impact, patient-reported outcomes, and other therapeutic features. The DCE results (phase B) 
showed that 10 criteria were relevant to the decision-making process for a 50- to 65-year-old DME patient: mean change in 
best corrected visual acuity (p value < 0.001), percentage of patients with an improvement of ≥ 15 letters (p value < 0.001), 
effect duration per administration (p value = 0.008), retinal detachment (p value < 0.001), endophthalmitis (p value = 0.012), 
myocardial infarction (p value < 0.001), intravitreal hemorrhage (p value = 0.021), annual treatment cost per patient (p 
value = 0.001), health-related quality of life (HRQoL) (p value = 0.004), and disability level (p value = 0.021).
Conclusions From a multi-stakeholder perspective, the selection of an appropriate treatment for DME patients should guar-
antee patient safety and maximize the visual acuity improvement and treatment effect duration. It should also contribute 
to system sustainability by being affordable, it should have a positive impact on HRQoL, and it should prevent disability.
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1 Introduction
Decision-making in healthcare is a highly complex process 
for stakeholders due to the presence of multiple factors and 
differing objectives that can influence the selection of a 
treatment or health intervention. To make optimal decisions, 
there is a need to integrate and prioritize all relevant crite-
ria. In addition to considering clinical efficacy and safety 
variables, there are other clinical and nonclinical factors 
that can influence treatment selection, such as costs, effi-
ciency, budgetary availability, patient-reported outcomes, 
and adherence to and persistence with treatment. Bypassing 
a formal decision-making process can result in variability, 
inconsistency, and a lack of transparency, which could lead 
to suboptimal decisions [1]. This process becomes even 
more complicated when the opinions of stakeholders from 
different fields are taken into account, such as the clinical, 
psychological, clinical management, health administration, 
and patient perspectives.
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Key Points for Decision Makers 
The introduction of new intravitreal treatments for retinal 
and vitreous diseases, including diabetic macular edema, 
has increased the complexity of clinical and economic 
management in the field of ophthalmology.
Multicriteria decision analysis is a set of techniques that 
can help to systematize decision-making in a structured 
way while increasing the consistency and transparency 
of decisions.
This work provides a useful framework for decision-
making in diabetic macular edema management that 
considers criteria according to the explicit preferences of 
the multiple stakeholders involved in this process.
administration. MCDA could aid decision-making in this 
environment, as it takes the perspectives of the different 
stakeholders into consideration.
The objective of this work was to determine the most rel-
evant criteria for decision-making in the treatment of DME 
patients by considering the perspectives of all the stakehold-
ers involved in this decision: physicians, hospital pharma-
cists, psychologists, experts in health management, local and 
national health authorities, and patient associations.
2  Methods
MCDA for the management of patients with DME was 
carried out according to the recommendations of The Pro-
fessional Society for Health Economics and Outcomes 
Research (ISPOR), which defines the techniques that can 
be used and the phases to be followed throughout a MCDA 
[1, 7].
This MCDA, which was termed the MULTIDEX-EMD 
study, was performed in three phases: an initial phase (phase 
A), where the criteria most relevant to the decision-making 
process in the treatment of DME were defined and selected; 
phase B, where the criteria were screened, weighted, and pri-
oritized; and phase C, where the results were discussed and 
the conclusions of the project were established in a delibera-
tive process. This study was carried out from February to 
May 2018 (Fig. 1).
Twenty participants were selected to develop the whole 
project. They were chosen based on their influence on 
healthcare decision-making at different levels and/or specific 
involvement with the disease. Four groups of stakeholders 
who were from different fields and therefore had different 
perspectives on DME-related decisions were identified: clin-
ical (7 physicians: 6 ophthalmologists specializing in retinal 
and vitreous disease and 1 endocrinologist), health man-
agement and health administration (3 representatives/former 
health authority representatives at national or regional levels, 
such as the Ministry of Health and Regional Health depart-
ments, and 3 health management experts representing medi-
cal management or hospital management positions and the 
academic field of health management and quality), hospital 
pharmacy (4 pharmacists), and the patient’s perspective (2 
members of patient associations and 1 clinical psychologist 
specializing in the management of people with diabetes). 
Invitations were sent out to determine the availability and 
willingness to participate of the experts initially selected. 
Because some of those experts were unavailable, additional 
experts were invited to participate until the required number 
of participants was reached. A breakdown of the participants 
involved in each phase of the study is shown in Fig. 1.
Multicriteria decision analysis (MCDA) offers the poten-
tial to overcome the challenges associated with traditional 
decision-making tools, especially for complex decisions 
that must consider multiple criteria, simultaneously evalu-
ate quantitative and qualitative information, and involve 
multiple stakeholders [2]. MCDA comprises a broad set of 
techniques that have been applied in various areas within and 
outside of the health sector and facilitate a rigorous approach 
to decision-making in complex environments. MCDA helps 
to increase the consistency and transparency of these deci-
sions. The techniques used in MCDA divide the decision-
making process into different stages in a structured way and 
explicitly incorporate the preferences of the participants in 
the process (stakeholders and influencers), thus providing 
clarity on the relevant criteria and their relative importance 
[1, 2].
Diabetic macular edema (DME) is an ocular complication 
of diabetes mellitus. This disorder involves the accumulation 
of fluid in the central portion of the retina as a consequence 
of the failure of the blood–retinal barrier [3]. This affects 
the sensitivity of the macular photoreceptor cells, leading 
to changes in vision and vision loss [4]. DME is the leading 
cause of visual impairment and blindness in people with dia-
betes [5], and its incidence in Spain has increased in recent 
years [6], similar to the incidence of diabetes. Currently, 
pharmacological management of DME consists of adminis-
tering corticosteroids or antiangiogenic drugs by intravitreal 
injection [3].
The arrival of new intravitreal treatments for retinal dis-
eases has increased the complexity of clinical and economic 
management in ophthalmology. Sustainability challenges 
have appeared as a result of the much higher costs of the 
new treatments and the organizational impact of intravitreal 
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2.1  Phase A: Defining the Criteria and Their Levels
This phase aimed to define the criteria of interest for deci-
sion-making in the management of a patient with DME and 
to establish the design of the subsequent analysis from these 
relevant criteria. A panel of experts was established; this 
panel then selected and defined the criteria.
During this phase, a questionnaire was developed that 
included a set of initially proposed criteria and their defi-
nitions. This questionnaire was sent to the participants for 
review, but it was also possible for participants to propose 
new criteria. Criteria were initially identified by means 
of a bibliographic review that included clinical trials of 
the options available, disease burden studies, and health 
technology assessment reports that were available for this 
pathology. Criteria that characterized a DME treatment 
were selected, such as efficacy, safety, costs, organizational 
impact, and economic impact. When identified criteria were 
similar, the more frequently used and comprehensive crite-
rion was selected to avoid duplication. Clinical and safety 
criteria were generally obtained from clinical trials, and 
focused on the main endpoints assessed in these studies. 
Each of the criteria had two or more possible levels; these 
levels characterize the criterion. After completing the ques-
tionnaire, the panel of experts had a face-to-face meeting 
aimed at reaching a consensus regarding the final criteria 
and their levels. The selected criteria served as the basis for 
the next phase of the study.
2.2  Phase B: Screening and Weighting the Criteria 
The main objective of this phase was to screen the criteria 
that were truly relevant to decision-making and to rank them 
by weighting their relative importance according to the pref-
erences of the participating stakeholders. This prioritization 
process was performed in reference to the case of a 50- to 
65-year-old diabetic patient with DME.
To obtain the preferences of the participants, the dis-
crete choice experiment (DCE) method was used, which 
was implemented according to international good practice 
recommendations [8, 9]. An electronic questionnaire was 
administered to 19 stakeholders (Fig. 1). The questionnaire 
was designed based on the combination of the criteria and 
levels selected in phase A and consisted of several ques-
tions or items. Each item comprised a pair of hypothetical 
treatments characterized by a unique combination of criteria 
levels.
For each item, the participants were asked to choose 
which of the two hypothetical treatments was the best option 
based on their preferences. The minimum necessary number 
of items (i.e., pair of hypothetical treatments) to establish 
the relevance of the criteria with sufficient statistical sig-
nificance was generated. For this purpose, an orthogonal 
design was chosen using the “Support.CEs” package [10]. 
This design was chosen due to a lack of prior information 
about whether there is a tendency of avoidance or preference 
towards the criteria. This design implies that each criterion 
level is compared with the rest of the criteria levels equally 
or proportionally.
Fig. 1  Phases of multicriteria 
decision analysis in diabetic 
macular edema management
Expert Panel
(12 participants)
Questionnaire + 
consensus meeting
Discrete Choice 
Experiment
(online questionnaire)
Fase A. Definition of 
criteria
Objective
Methods Final meeting: 
deliberative process
Selection and 
definition of criteria
Ranking and weighting 
of criteria
Discussion and 
consensus about the 
results
Participants Expert Panel
(14 participants)
Multiple 
stakeholders
(19 participants)
Fase B. Criteria 
screening
Fase C. Deliberative 
process
• 3 ophthalmologists
• 4 hospital pharmacists
• 3 health management 
experts
• 3 health authority 
representatives
• 1 clinical psycologist
• 6 ophthalmologists
• 1 endocrinologist
• 4 hospital pharmacists
• 3 health management 
experts
• 2 health authority 
representative
• 2 patient association 
representatives
• 1 clinical psycologist
• 4 ophthalmologists
• 1 endocrinologist
• 2 hospital pharmacists
• 3 health management 
experts
• 1 health authority 
representative
• 1 clinical psycologist
February 2018 March-May 2018 May 2018
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To facilitate the completion of the questionnaire, the 
items were divided into several blocks, which generated four 
different questionnaires to be completed by the stakeholders.
After obtaining the answers to the questionnaires, two 
statistical analyses were carried out by fitting multinomial 
logit models—one to screen the criteria according to their 
relevance and the other to estimate the weights. The back-
ward elimination algorithm was used to fit the general model 
used to screen the criteria. This algorithm was based on a 
complex general model (with a large number of criteria), 
and it sequentially eliminated the criteria with the largest 
p values until all of the criteria included in the model had 
statistically significant p values (p < 0.05). A second multi-
nomial logit model was then fitted to estimate the weights 
of the screened criteria.
The relative importance index was used to weight the 
criteria:
 where 훽
Di
 is the estimator domain i and  WDi is the percent-
age of weight domain i.
All statistical analyses were performed using R software 
(version 3.2.3, R Foundation for Statistical Computing, 
Vienna, Austria) [11].
After analyzing the answers to the questionnaires, the 
model that best predicted the decision-making process was 
established by selecting the most relevant criteria. In this 
model, each criterion was weighted based on the choice pref-
erences of the participants.
2.3  Phase C: Deliberative Process
The final phase of the MCDA involved presenting the results 
and discussing and interpreting the screened criteria and 
their weights according to the preferences of the partici-
pants. The conclusions of the analysis were also established 
during this phase through a face-to-face meeting involving 
12 of the stakeholders from the panel of experts (Fig. 1). The 
comments and conclusions that emerged from this meeting 
about the study and the respective results are included in 
Sect. 4 below.
3  Results
3.1  Defining the Criteria and Their Levels
In phase A, after the initial meeting, the panel of experts estab-
lished and defined a total of 31 possible criteria that could 
be relevant in the management of patients with DME. These 
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criteria and their levels are detailed in Table 1. Throughout the 
study, the criteria were divided into five categories to help the 
participants to manage them in a more structured way, con-
sidering the large number of criteria involved. However, the 
criteria were considered independently, and the importance of 
each criterion was weighted individually. The categories were 
efficacy/effectiveness, safety, organizational and economic 
impact, patient-reported outcomes (patient and caregiver), and 
other therapeutic features. By combining the levels of the 31 
selected criteria, a set of 120 pairs of hypothetical treatments 
corresponding to the items of the DCE questionnaire were 
obtained using an orthogonal design.
3.2  Criteria Screening
The results of the DCE indicated that 10 of the 31 criteria 
were considered relevant to decision-making in the manage-
ment of a 50- to 65-year-old diabetic with macular edema 
(Table 2). In the fitted logit model, three of the seven effi-
cacy/effectiveness criteria (those related to visual acuity and 
duration of effect) were statistically significant according 
to the analysis. Of the eight safety criteria selected, four 
were relevant (three ocular adverse events and one systemic 
adverse event). In relation to the patient-reported outcomes 
provided by the patient and/or caregiver, two of the five cri-
teria were relevant (health-related quality of life and dis-
ability). Finally, only one (annual pharmaceutical cost per 
patient) of the six criteria relating to the organizational and 
economic impact established in phase A was statistically 
significant in the analysis.
3.3  Criteria Weighting
The screened criteria that had statistically significant coef-
ficients were fitted using a logit model to estimate the weight 
of each criterion that was relevant to the decision-making 
process for the management of DME patients. Figure 2 
shows the relative weight of each criterion. The considered 
criteria relating to safety constituted 47% of the overall 
weight in decision-making, and 35% when all the efficacy/
effectiveness criteria were considered. The criteria concern-
ing patient-reported outcomes accounted for 11% of the total 
weight, and the criterion associated with organizational and 
economic impacts comprised 7% of the overall weight.
The most relevant criterion for decision-making in the 
treatment of patients with DME was the mean change in 
best corrected visual acuity (BCVA) (5-letter improvement), 
pertaining to efficacy (weight: 17%). This was followed by 
adverse event criteria such as retinal detachment (16%) and 
acute myocardial infarction (13%). Another efficacy-related 
criterion with a high weight was a ≥ 15 letter improvement 
in BCVA (12%). The remaining criteria had weights of less 
than 10%.
Multi-stakeholder MCDA for DME Management
Table 1  List of selected criteria for decision-making in diabetic macular edema management
Criteria Levels
Efficacy/effectiveness
 Mean change in BCVA (5-letter improvement) 0–5 letters
6–10 letters
11–15 letters
> 15 letters
 ≥ 15 letter improvement in BCVA 0–15% patients
16–30% patients
> 30% patients
 Reduction in central retinal thickness ≤ 20% reduction
> 20% reduction
 Speed of action: visual acuity improvement < 1 month
1–3 months
> 3 months
 Effect duration per administration ≤ 1 month
> 1–4 months
> 4–12 months
> 12 months
 Response in patients who were previously treatment refractory Response is maintained after change of treatment due to lack of response
Response is improved after change of treatment due to lack of response
Response is reduced after change of treatment due to lack of response
 Reduction in the need for long-term treatment (3 years) Yes
No
Safety
 Ocular adverse events: increased intraocular pressure Occurrence: controlled with medical treatment
Occurrence: controlled with surgical treatment
Nonoccurrence
 Ocular adverse events: endophthalmitis Occurrence
Nonoccurrence
 Ocular adverse events: retinal detachment Occurrence
Nonoccurrence
 Ocular adverse events: vitreous hemorrhage Occurrence
Nonoccurrence
 Ocular adverse events: cataract Occurrence
Nonoccurrence
Progression
 Systemic adverse events: acute myocardial infarction Occurrence
Nonoccurrence
 Systemic adverse events: cerebrovascular accident Occurrence
Nonoccurrence
 Immunogenicity Occurrence
Nonoccurrence
Organizational and economic impact
 Budget impact Positive (increased costs in the budget)
Neutral (no increased costs nor cost savings in the budget)
Negative (cost savings in the budget)
 Annual treatment cost per patient < €500
€500–1500
> €1500–3000
> €3000
 F. de Andrés-Nogales et al.
4  Discussion
MCDA enables the establishment of a framework that stake-
holders can use as a tool to probe the full range of DME 
treatment existing preferences and to systematize transpar-
ent decision-making. In this sense, the present study could 
serve as the basis for DME treatment selection, ensuring 
that there is a multistakeholder perspective that covers the 
criteria that are important to all decision-makers involved, 
rather than focusing only on the viewpoint of physicians 
or health authorities/payers. The results of this analysis 
highlight the overall importance of DME treatment safety 
to the stakeholders involved in this project; its relevance 
BCVA best-corrected visual acuity
a The caregiver is occasionally required to accompany the patient during visits relating to pharmacological treatment
b The caregiver is frequently or always required to accompany the patient during visits relating to pharmacological treatment
Table 1  (continued)
Criteria Levels
 Number of intravitreal injections (first year) ≤ 3
> 3
 Minimum required facilities Clean room
Surgery room
 Healthcare burden (need of use of resources, such as visits, 
injections, or tests)
The treatment implies an increase in the healthcare burden
The treatment does not modify the healthcare burden
The treatment implies a reduction in the healthcare burden
 Need of pharmacy handling Pharmacy handling
No pharmacy handling
Patient-reported outcomes (patient and caregiver)
 Disability Improvement in functional capacity and performance of activities of daily 
living
No effect on functional capacity and performance of activities of daily living
Worsening of functional capacity and performance of activities of daily living
 Health-related quality of life Improvement in quality of life (social/occupational)
No effect on quality of life (social/occupational)
Worsening of quality of life (social/occupational)
Effect on emotional state Anxiety and depression treated pharmacologically
Anxiety and depression treated nonpharmacologically
No anxiety or depression
 Treatment satisfaction Improvement
No effect
Worsening
 Caregiver burden (related to the pharmacological treatment) No increase in the caregiver burden
Moderate increase in the caregiver  burdena
High increase in the caregiver  burdenb
Other therapeutic features
 Treatment persistence Persistent patient
Nonpersistent patient
 Pharmaceutical form Modified or delayed release
No modified release
 Available presentations Vial
Syringe/injector
Vial and syringe/injector
 Therapeutic innovation: new mechanism of action Yes
No
 Therapeutic innovation: new therapeutic target Yes
No
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to decision-making accounted for almost half of the total 
weight across all criteria.
Although currently available treatments are considered 
very safe from the physician’s perspective, and there is no 
concern over their use or the management of possible events, 
the potential for the patient to suffer a serious adverse event 
could be a determining factor in the choice of treatment 
when a decision is made considering a broader perspective 
involving different stakeholders viewpoints. Another impor-
tant aspect was found to be the efficacy of the therapeutic 
alternatives. Indeed, the ability to change the BCVA was the 
most important criterion, mainly because it is directly related 
to the visual capacity of the patient.
An important and positive aspect of MCDA is that it 
integrates existing methodologies that are widely used in 
other fields. Several recommended techniques with different 
complexities and theoretical foundations can be used to iden-
tify preferences, such as the analytic hierarchical process, 
DCE, and conjoint analysis [1]. DCE is an instrument with 
a strong theoretical foundation, so, unlike other techniques, 
it adds considerable robustness to the process of screening 
and prioritizing the criteria in a MCDA. In this study, cri-
teria selection was based on the available evidence and the 
Table 2  Results of the adjusted multinomial logit model
BCVA best corrected visual acuity
Estimator Standard error t value p value
Constant 0.07 0.109 0.64 0.522
Mean change in BCVA (5-letter improvement) 0.77 0.118 6.513 < 0.001
≥ 15 letter improvement in BCVA 0.53 0.102 5.213 < 0.001
Effect duration per administration − 0.254 0.096 − 2.639 0.008
Ocular adverse events: endophthalmitis 0.417 0.166 2.509 0.012
Ocular adverse events: retinal detachment 0.697 0.172 4.041 < 0.001
Ocular adverse events: vitreous hemorrhage 0.392 0.17 2.307 0.021
Systemic adverse events: myocardial infarction 0.574 0.162 3.551 < 0.001
Annual treatment cost per patient 0.306 0.092 3.335 0.001
Disability level − 0.211 0.091 − 2.306 0.021
Health-related quality of life 0.253 0.087 2.919 0.004
Log-likelihood McFaddens R2 Likelihood ratio test
Goodness-of-fit model information − 253.84 − 0.202 128.452 (10 gl)
p < 0.001
Fig. 2  Relevant criteria for deci-
sion-making in diabetic macular 
edema management (50- to 
65-year-old patient). BCVA best 
corrected visual acuity
General decision model: 
50- to 65-year-old diabetic 
patient with macular edema
Efficacy/Effectiveness
Mean change in BCVA (5-letter improvement) (p<0.001) 17%
≥15 letter improvement in BCVA (p<0.001) 12%
Effect duration per administration (p=0.008) 6%
35%
Safety
Retinal detachment (p<0.001) 16%
Acute myocardial infarction (p<0.001) 13%
Vitreous haemorrhage (p=0.021) 9%
Endophthalmitis (p<0.012) 9%
47%
Organisational and 
economic impact Annual treatment cost per patient (p<0.001) 7%7%
Patient-Reported 
Outcomes
Health-related quality of life (p=0.004) 6%
Disability (p=0.021) 5%
11%
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characteristics of the current DME treatments. Identifying 
specific criteria rather than using sets of generic criteria 
addresses and defines the health issue and the characteristics 
of the possible treatments more precisely without excluding 
any specific relevant criterion.
This analysis is not without limitations. In any analy-
sis, the results are determined by the data available. In this 
sense, the weighting of the established criteria is subject 
to uncertainty, as it is influenced by the number of partici-
pating experts and, above all, by the proportion of those 
participants in each stakeholder group. The objective of 
the study was to provide a global perspective as an aid to 
decision-making in the treatment of DME, so the results 
from all stakeholder groups were included but they were 
aggregated to give the most representative multistakeholder 
perspective on DME treatment possible. However, it could 
be interesting to carry out a specific study to determine the 
criteria that were prioritized by each group of stakeholders. 
In addition, the prioritization of the criteria by each par-
ticipant may have been influenced by their interpretation of 
the criteria included in the analysis and the levels included 
for each criterion. This interpretation would depend on the 
stakeholder group to which they belong and their familiar-
ity with or knowledge of each criterion. To account for this, 
definitions of and information on the criteria were included 
in the questionnaires for each phase to aid participant under-
standing. MCDAs can be used to support health decision-
making in multiple ways, for example in health planning 
and research, in the pricing and financing of health tech-
nologies, and in treatment selection [1, 2, 12]. According to 
statistics reported in [12], more than half of all healthcare-
related MCDAs have been performed to support decisions 
regarding health intervention reimbursement and coverage. 
Another frequent reason for applying MCDA in healthcare is 
to inform decisions regarding the selection or prioritization 
of treatments. The main areas in which MCDAs are applied 
are in the diagnosis and treatment of pathologies, prioritiza-
tion policies, and the evaluation of health technologies [2]. 
MCDAs have been used by various public and private health 
technology assessment organizations and agencies in differ-
ent countries [13], such as Germany [14], Norway [15], Italy 
[16], Australia [17], and Thailand [18, 19].
In our country, Spain, only a few MCDAs have been 
published in the field of healthcare [20–28], although the 
number of healthcare-related publications that incorporate 
MCDA is increasing in Spain and globally.
To our knowledge, this is the first MCDA to be conducted 
on the management of DME as well as in the field of oph-
thalmology in Spain. The literature on the application of 
MCDA to DME or indeed ophthalmology in general is cur-
rently very limited. Recently in Italy, a MCDA was devel-
oped for the treatment of DME with the aim of complement-
ing health technology assessment in several regions of the 
country [29–32]. This study included two phases: (a) the 
criteria were prioritized based on the general model from 
the European Network for Health Technology Assessment 
(EUnetHTA), and (b) each of the alternatives was scored 
according to its performance (which was assessed based on 
the previously prioritized criteria). One of the main differ-
ences of that study from the present work is that the former 
MCDA was developed according to the EVIDEM (Evidence 
and Value: Impact on Decision-Making) methodology, 
which involved comparative scoring of the alternatives and 
criteria prioritization using a direct classification method 
instead of a decompositional method such as a DCE. How-
ever, both studies found that safety criteria were assigned the 
highest priority, whereas efficacy was considered to be less 
of a priority than other criteria such as economic impact and 
general relevance. The results of that study concluded that, 
according to the perspectives of the stakeholders involved, 
dexamethasone could be the most advantageous treatment 
option, as it yielded the highest score based on the multiple 
criteria selected in the MCDA.
A MCDA that evaluated the most relevant health out-
comes of opioid substitution treatment programs in patients 
with disorders resulting from opioid use was recently devel-
oped in Spain [21]. That study followed the same method-
ology as the present MCDA: the relevant criteria and their 
weights were established by identifying the preferences of 
experts through a DCE. The main differences of that study 
from the present analysis are that the aim of the former study 
was to evaluate exclusively health outcomes from a clini-
cal perspective instead of including different stakeholders. 
One of the most interesting aspects of that study was that 
the analysis was conducted using different patient profiles, 
which led to different criteria weighting in each case.
Some MCDAs have been used in our country to com-
pare alternative treatments for various pathologies, such as 
chronic dermatological inflammatory diseases, cancer, rare 
diseases, and cardiovascular diseases such as nonvalvular 
atrial fibrillation and pulmonary hypertension [24–26, 28]. 
Other applications of MCDA include the development of an 
assessment framework for rare diseases at a regional level 
in Catalonia [22] and the development of a decision-support 
tool for drug evaluation in a pharmacy and therapeutics com-
mittee setting at the hospital level [20]. MCDA was also 
used to establish an algorithm for predicting price and reim-
bursement decisions at national and regional levels [27].
Some studies have used the EVIDEM methodology to 
develop the analysis [20, 22–25, 28]. In those studies, the 
methods used to prioritize the criteria were fundamentally 
compositional, such as direct classification or the analytic 
hierarchical process [22–28]. Either a single-stakeholder 
perspective was used, such as that of patients [20, 21, 26] 
or evaluation agencies [22, 27], or a multidisciplinary 
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perspective was employed, which included patients, physi-
cians, and other stakeholders [23–25, 28].
5  Conclusions
According to the preferences of the multiple stakeholders 
involved, an appropriate DME treatment should guarantee 
the safety of the patient while maximizing improvements in 
their visual acuity for the longest effect duration. In addition, 
the DME treatment should have an affordable annual cost 
that contributes to the health system sustainability. Finally, 
it should have a positive impact on the health-related quality 
of life of the patient and prevent the onset or progression of 
disability.
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